Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Anna SuredaMei-Jie ZhangPeter DregerJeanette CarrerasTimothy FenskeHerve FinelHarry SchoutenSilvia MontotoStephen RobinsonSonali M SmithAriane BoumedilMehdi HamadaniMarcelo C PasquiniPublished in: Cancer (2018)
Allo-HCT should be considered for patients with relapsed FL and available HLA-matched donors. Outcomes are better in earlier phases of the disease, and reduced-intensity conditioning should be preferred. The prognostic score presented here can assist in counseling patients and determining the time to proceed to transplantation. Cancer 2018;124:1733-42. © 2018 American Cancer Society.
Keyphrases
- diffuse large b cell lymphoma
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- acute myeloid leukemia
- papillary thyroid
- end stage renal disease
- squamous cell
- hodgkin lymphoma
- newly diagnosed
- chronic kidney disease
- ejection fraction
- stem cells
- prognostic factors
- type diabetes
- squamous cell carcinoma
- young adults
- hepatitis c virus
- smoking cessation
- hiv infected
- data analysis